Public health issues of hepatitis C virus infection.
暂无分享,去创建一个
[1] D. Holtzman,et al. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. , 2012, Annals of internal medicine.
[2] N. Pai,et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review , 2012, Sexually Transmitted Infections.
[3] Michael J. O'Grady,et al. Economic model of a birth cohort screening program for hepatitis C virus , 2012, Hepatology.
[4] P. Grime,et al. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data , 2012, Journal of viral hepatitis.
[5] J. Ward,et al. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings , 2012, Annals of Internal Medicine.
[6] Peter J. Richardson,et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. , 2012, Journal of hepatology.
[7] C. Mcgowan,et al. Barriers to hepatitis C treatment , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[8] D. Berg. 3.13.1 THE EUROPEAN EXPERIENCE , 2012 .
[9] P. Vickerman,et al. Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.
[10] G. Torre,et al. Hepatitis C Virus infections trends in Italy, 1996-2006 , 2011, Hepatitis monthly.
[11] M. Alter. HCV routes of transmission: what goes around comes around. , 2011, Seminars in liver disease.
[12] M. Buti,et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * , 2011, Journal of viral hepatitis.
[13] Louisa Degenhardt,et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.
[14] M. Buti,et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[15] Joan M. Block,et al. Is chronic hepatitis B being undertreated in the United States? , 2011, Journal of viral hepatitis.
[16] P. Belperio,et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] P. Vickerman,et al. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. , 2011, Journal of hepatology.
[18] Axel Rahmel,et al. The European experience , 2011, Transplant international : official journal of the European Society for Organ Transplantation.
[19] M. Alter,et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. , 2011, Archives of internal medicine.
[20] S. Smith,et al. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression , 2010, Alimentary pharmacology & therapeutics.
[21] S. Holmberg,et al. Is sexual contact a major mode of hepatitis C virus transmission? , 2010, Hepatology.
[22] H. M. Colvin,et al. Institute of Medicine recommendations for the prevention and control of hepatitis B and C , 2010, Hepatology.
[23] M. Alter,et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. , 2010, Gastroenterology.
[24] J. Desenclos,et al. The impact of the prevention programme of hepatitis C over more than a decade: the French experience , 2009, Journal of viral hepatitis.
[25] A. Valleron,et al. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives , 2009, Statistical methods in medical research.
[26] M. Ghany,et al. Diagnosis, management, and treatment of hepatitis C: An update , 2009, Hepatology.
[27] D. Lavanchy,et al. The global burden of hepatitis C , 2009, Liver international : official journal of the International Association for the Study of the Liver.
[28] D. Vlahov,et al. Limited Uptake of Hepatitis C Treatment Among Injection Drug Users , 2008, Journal of Community Health.
[29] J. Desenclos,et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. , 2008, Journal of hepatology.
[30] D. De Angelis,et al. The burden of hepatitis C in England , 2007, Journal of viral hepatitis.
[31] M. Alter,et al. Epidemiology of hepatitis C virus infection. , 2007, World journal of gastroenterology.
[32] M. Alter,et al. Infectivity of Hepatitis C Virus in Plasma After Drying and Storing at Room Temperature , 2007, Infection Control & Hospital Epidemiology.
[33] K. Neal. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study , 2007, Gut.
[34] J B Wong,et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States , 2007, Journal of viral hepatitis.
[35] M. Alter,et al. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.
[36] L. Fraenkel,et al. What do patients consider when making decisions about treatment for hepatitis C? , 2005, The American journal of medicine.
[37] A. Hatzakis,et al. Future trends of HCV‐related cirrhosis and hepatocellular carcinoma under the currently available treatments , 2005 .
[38] M. Buti,et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. , 2005, Journal of hepatology.
[39] G. Dore,et al. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[40] R. Zachoval,et al. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] S. Glynn,et al. A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.
[42] S. Mauss,et al. A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance , 2004, Hepatology.
[43] S. Zickmund,et al. Hepatitis C virus‐infected patients report communication problems with physicians , 2004, Hepatology.
[44] Y. Hutin,et al. The global burden of disease attributable to contaminated injections given in health care settings , 2004, International journal of STD & AIDS.
[45] G. Davis,et al. Projecting future complications of chronic hepatitis C in the United States , 2003, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[46] A. Lok,et al. Identification and Management of Hepatitis C Patients in Primary Care Clinics , 2003, American Journal of Gastroenterology.
[47] John B. Wong,et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C , 2003 .
[48] E. Roberts,et al. Maternal‐infant transmission of hepatitis C virus infection , 2002, Hepatology.
[49] S. Sonnad,et al. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey , 2001, Journal of viral hepatitis.
[50] M. Backmund,et al. Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.
[51] M. Buti,et al. Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. , 2000, Journal of hepatology.
[52] M. Abdel-hamid,et al. Hepatitis C virus (HCV) infection in a community in the nile delta: Population description and HCV prevalence , 2000, Hepatology.
[53] L. Magder,et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.
[54] F. Gordon,et al. Cost-effectiveness of screening patients for hepatitis C. , 1999, The American journal of medicine.
[55] L. Seeff,et al. Natural history of hepatitis C , 1997, Hepatology.
[56] S. Zeuzem,et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.
[57] M. Jadoul,et al. Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission. , 2012, Contributions to nephrology.
[58] R. Elston,et al. Oral combination therapy: Future hepatitis C virus treatment? , 2011 .
[59] D. Harnois,et al. Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .
[60] A. Hatzakis,et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. , 2004, Journal of viral hepatitis.
[61] M. Manns,et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. , 2003, Gut.
[62] R. Esteban,et al. Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.
[63] G. Cilla,et al. Maternal-infant transmission of hepatitis C virus infection. , 1992, The Pediatric infectious disease journal.